FFL Partners announced that it has completed a growth investment in Apex Infusion, a fast-growing provider of ambulatory infusion therapy services.
Founded in 2006 and headquartered in Signal Hill, California, Apex Infusion is dedicated to providing high-quality, reliable care to patients in the comfort of their own homes or in ambulatory settings. Apex coordinates professional interaction with patient’s physicians, nurses and other health care providers. The company provides intravenous immunoglobulin, specialty infusion, total parental nutrition and other therapeutic services. Apex currently operates 11 locations in California.
Founded in 1997, FFL Partners is a San Francisco-based private equity firm with more than $5 billion under management. FFL is a hyperspecialized, thematic investor focused on targeted areas within healthcare and tech-enabled services.
“We look forward to accelerating our growth in partnership with FFL,” said Moussie Hailemariam, Chief Executive Officer of Apex Infusion. “We have already begun mapping out areas to expand geographically through de novo locations, as well as strategic acquisitions to build scale.”
“Apex Infusion is a well-operated infusion provider focused on delivering a high-quality patient and doctor experience,” said Karen Winterhof, Partner at FFL. “We’re pleased to work closely with their talented management team as they seek to meet the critical needs of patients with chronic illnesses, while building a leading diversified specialty infusion platform.”
According to data captured in the LevinPro HC database, this acquisition marks the eighth infusion services transaction of 2024. There were eight deals announced in the infusion services specialty during 2023, and 32 announced in the specialty during 2022. Financial terms of the transaction were not disclosed.
